Kartick Patra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kartick Patra has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Adel Mandl
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD
116 shared publications - Aliya Lalji
Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 1
116 shared publications - Catherine Handy Marshall
Sidney Kimmel Comprehensive Cancer Center 1 Baltimore, Maryland
116 shared publications - Channing Judith Paller
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
116 shared publications - Christopher Hoimes
Department of Medicine Duke Cancer Institute Durham North Carolina USA
116 shared publications - Dominique A. Garrison
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
116 shared publications
Latest Publications
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S3 shows Adverse Events Included in the Co-Primary Endpoint: All Occurrences
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S3 shows Adverse Events Included in the Co-Primary Endpoint: All Occurrences
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S9 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S9 shows FACT-P Total Scores: Baseline, Cycles 4, 6, and 8
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S9 shows FACT-P Total Scores: Baseline, Cycles 4, 6, and 8
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary: Trial Protocol from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Trial Protocol shows the details of the study
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary: Trial Protocol from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Trial Protocol shows the details of the study
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6
- Open Access
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo
- 26 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo